Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
AlzeCure Pharma Logo
AlzeCure Pharma Growth Score
70
CB Rank
11832
Heat Score
91
The AlzeCure Foundation is focused on the development of novel diagnostics and therapeutics for PD.
Founded
obfuscation
PublicPost-IPO Equity Stockholm, Stockholms Lan, Sweden1-10 www.alzecurepharma.se/sv/
Health Care
Medical
Pharmaceutical
Overview

AlzeCure Pharma
Total Funding
obfuscation
Growth Score
70
Heat Score
91

Total Funding
obfuscation
obfuscation
Post-IPO Equity raised
obfuscation
Growth Score70
-2 pts
in past quarter
Heat Score 91
19 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About AlzeCure Pharma

CB Rank
11832
The AlzeCure Foundation is focused on the development of novel diagnostics and therapeutics for PD.
Founded
obfuscation
PublicPost-IPO Equity Stockholm, Stockholms Lan, Sweden1-10 www.alzecurepharma.se/sv/
Health Care
Medical
Pharmaceutical

Funding Rounds

Post-IPO Equity
OBF
in
obfuscation
Post-IPO Equity
OBF
in
obfuscation
Grant
OBF
in
obfuscation

Key People

Details

Legal Name AlzeCure Pharma AB
Operating Status Active
Stock Symbol  STO:ALZCUR
Company Type For Profit
About the Company
The AlzeCure Foundation is focused on the development of novel diagnostics and therapeutics for PD, AD and related neurodegenerative disorders. Conceptually, AlzeCure is an industry-standard incubator for novel projects. It comprises key professionals exhibiting complementary expertise from molecule to man.
Phone Number +46 (0) 703-73 88 24.
Predictions & Insights

Growth Insight

See this Growth Insight
AlzeCure Pharma is
Lorem
 to be growing
Top Contributing Factors
Recently Raised Funding

Growth Prediction

See this Growth Prediction
Top Contributing Factors
Runway Speculation

Products & Services

NeuroRestore ACD856
A small molecule drug candidate enhancing neurotrophin signaling to improve cognition and potentially modify disease progression in Alzheimer's and other cognitive disorders.
ACD440
A TRPV1 antagonist developed as a topical treatment for neuropathic pain, aiming to provide local analgesic effects with minimal systemic exposure.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
1
obfuscation
QuantumCellPost-IPO Equity
obfuscation
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
1
obfuscation
QuantumCellPost-IPO Equity
obfuscation
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
1
obfuscation
QuantumCellPost-IPO Equity
obfuscation
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
1
obfuscation
QuantumCellPost-IPO Equity
obfuscation
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
1
obfuscation
QuantumCellPost-IPO Equity

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 5
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
1
obfuscation
QuantumCellPost-IPO Equity
obfuscation
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
1
obfuscation
QuantumCellPost-IPO Equity
obfuscation
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
1
obfuscation
QuantumCellPost-IPO Equity
obfuscation
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
1
obfuscation
QuantumCellPost-IPO Equity
obfuscation
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
1
obfuscation
QuantumCellPost-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
QuantumCell Logo
QuantumCell
Yes
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
—
QuantumCell Logo
QuantumCell
Yes
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
—
QuantumCell Logo
QuantumCell
Yes
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
—
QuantumCell Logo
QuantumCell
Yes
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
—
QuantumCell Logo
QuantumCell
Yes
Post-IPO Equity - AlzeCure Pharma Logo
Post-IPO Equity - AlzeCure Pharma
—
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 4 Board Members and Advisors 1 Contacts 5

Employee Profiles

Board Members and Advisors

News

News and Press

News•Jul 6, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 2, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
News•Jul 1, 2026
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

5,003
12%
 in past month

IT Spend

$116.8KThis year, AlzeCure Pharma is projected to spend $116.8K on IT, according to Aberdeen.

Active Website Tech Count

18AlzeCure Pharma is actively using 18 technologies for its website, according to BuiltWith. These include Google Tag Manager, HSTS, and  WordPress.

Total IP

18The intellectual property of AlzeCure Pharma includes 13 registered patents primarily in the 'Medical Or Veterinary Science; Hygiene' category, according to IPqwery. Additionally, AlzeCure Pharma has registered 5 trademarks with the most popular class being 'Scientific and technological services', according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is AlzeCure Pharma's headquarters? AlzeCure Pharma is located in Stockholm, Stockholms Lan, Sweden.Who invested in AlzeCure Pharma? AlzeCure Pharma has 9 investors including QuantumCell and  European Innovation Council.When was the last funding round for AlzeCure Pharma? AlzeCure Pharma closed its last funding round on
obfuscation
from a Post-IPO Equity round.Who are AlzeCure Pharma's competitors? Alternatives and possible competitors to AlzeCure Pharma may include Retro Biosciences, MapLight Therapeutics, and  LEXEO Therapeutics.How much funding has AlzeCure Pharma raised to date? AlzeCure Pharma has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(f7db04b 1)
|